An Exploratory Study by Fast CAR T Cells

Dose-limiting toxicity(DLT)

The main goal of this trial is to evaluate the safety and tolerability of CAR T cell therapy
 for advanced solid tumors with positive mesothelin and MUC1.Patients were screened,
 peripheral blood mononuclear cells (PBMC) were isolated from eligible patients, and cells
 were prepared. Pretreatment was performed within 5 days before infusion, and CAR T cells were
 infused on day 0 (the dose was determined according to the requirements of
 climbing/expansion). The safety intensive observation period was 28 days after infusion, and
 the clinical efficacy after infusion was evaluated on days 28-34. The follow-up observation
 and evaluation were carried out according to the follow-up visit point, and the follow-up
 period was 1 year. From the second year, the telephone follow-up period was entered.